Diabetic Ketoacidosis Treatment Guidelines

Initial Management

• The American Diabetes Association recommends aggressive fluid resuscitation with isotonic saline at a rate of 15-20 mL/kg/hour to restore circulatory volume and tissue perfusion in patients with diabetic ketoacidosis (DKA) 1, 2
• Continuous intravenous insulin infusion is the standard of care for critically ill and mentally obtunded patients with DKA, according to the American Diabetes Association 3, 4
• Identifying and treating any correctable underlying cause of DKA, such as sepsis, myocardial infarction, or stroke, is crucial for effective management, as recommended by the American Diabetes Association 3, 1

Fluid Management

• The American Diabetes Association suggests that after initial volume expansion with isotonic saline, subsequent fluid choice depends on hydration status and electrolyte levels in patients with DKA 2
• When serum glucose reaches 250 mg/dL, changing fluid to 5% dextrose with 0.45-0.75% NaCl while continuing insulin therapy can help resolve ketosis, according to the American Diabetes Association 2

Insulin Therapy

• For critically ill patients, administering continuous intravenous regular insulin at an initial rate of 0.1 units/kg/hour is recommended by the American Diabetes Association 1
• The American Diabetes Association recommends continuing insulin therapy until resolution of ketoacidosis (pH >7.3, serum bicarbonate ≥18 mEq/L, and anion gap ≤12 mEq/L) regardless of glucose levels 1, 2
• For mild or moderate uncomplicated DKA, subcutaneous rapid-acting insulin analogs combined with aggressive fluid management can be as effective as intravenous insulin, according to the American Diabetes Association 3

Electrolyte Management

• Monitoring potassium levels closely is essential, as insulin administration can cause hypokalemia, according to the American Diabetes Association 1, 2
• Including 20-30 mEq/L potassium (2/3 KCl and 1/3 KPO₄) in the infusion once renal function is assured is recommended by the American Diabetes Association 5
• Maintaining serum potassium between 4-5 mmol/L is crucial for effective management, according to the American Diabetes Association 1, 2

Monitoring During Treatment

• Drawing blood every 2-4 hours to determine serum electrolytes, glucose, blood urea nitrogen, creatinine, osmolality, and venous pH is recommended by the American Diabetes Association 3, 2
• Following venous pH and anion gap to monitor resolution of acidosis is essential, according to the American Diabetes Association 1, 2
• Direct measurement of β-hydroxybutyrate in blood is the preferred method for monitoring DKA, as recommended by the American Diabetes Association 1, 2

Resolution Parameters

• DKA resolution requires glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, venous pH >7.3, and anion gap ≤12 mEq/L, according to the American Diabetes Association 3, 2
• Ketonemia typically takes longer to clear than hyperglycemia, as noted by the American Diabetes Association 1, 2

Transition to Subcutaneous Insulin

• When transitioning to subcutaneous insulin, administering basal insulin 2-4 hours before stopping the intravenous insulin can prevent recurrence of ketoacidosis and rebound hyperglycemia, according to the American Diabetes Association 3, 4
• Recent studies have reported that the administration of a low dose of basal insulin analog in addition to intravenous insulin infusion may prevent rebound hyperglycemia without increased risk of hypoglycemia, as noted by the American Diabetes Association 3

Discharge Planning

• Developing a structured discharge plan tailored to the individual patient is essential, according to the American Diabetes Association 3, 6
• Ensuring medication reconciliation with cross-checking of home and hospital medications is crucial, as recommended by the American Diabetes Association 3
• Scheduling follow-up appointments prior to discharge can increase the likelihood of attendance, according to the American Diabetes Association 3, 6
• Transmitting discharge summaries to the primary care clinician as soon as possible after discharge is recommended by the American Diabetes Association 3, 6

Insulin Bolus in Diabetic Ketoacidosis Management

Adult DKA Management Protocol

• The American Diabetes Association recommends that for adult patients with diabetic ketoacidosis (DKA), an intravenous bolus of regular insulin at 0.15 units/kg body weight is administered before starting the continuous insulin infusion, provided that hypokalemia (low potassium levels) is excluded 7, 8, 9
• For adult patients with moderate to severe DKA, administer an intravenous bolus of regular insulin at 0.15 units/kg body weight, followed by a continuous infusion of regular insulin at 0.1 unit/kg/hour (typically 5-7 units/hour in adults) 7, 8, 9
• The bolus dose should only be given after confirming serum potassium is ≥3.3 mEq/L to prevent potentially dangerous hypokalemia 9

Monitoring and Adjustment

• If plasma glucose does not fall by 50 mg/dL from the initial value in the first hour, check hydration status; if acceptable, double the insulin infusion rate every hour until achieving a steady glucose decline of 50-75 mg/hour 7, 9

Special Considerations

Pediatric Patients

• An initial insulin bolus is NOT recommended for pediatric patients with DKA 7, 9
• For children, start directly with a continuous insulin infusion at 0.1 unit/kg/hour without a bolus dose 9

Mild DKA

• For mild DKA cases, regular insulin may be given subcutaneously or intramuscularly instead of intravenously 8
• In mild cases, start with a "priming" dose of regular insulin of 0.4-0.6 units/kg body weight, half as an intravenous bolus and half as a subcutaneous or intramuscular injection 8

Evidence Considerations

Benefits of Bolus Insulin

• The low-dose insulin regimen (bolus followed by continuous infusion) decreases plasma glucose concentration at a rate of 50-75 mg/dL/hour, similar to higher-dose insulin regimens 7, 8
• The bolus helps to rapidly achieve therapeutic insulin levels in the bloodstream 8, 9

Important Caveats

• Ketonemia typically takes longer to clear than hyperglycemia, so insulin therapy must continue until ketoacidosis resolves, even if blood glucose normalizes 7, 9
• Direct measurement of β-hydroxybutyrate in blood is the preferred method for monitoring DKA resolution, as the nitroprusside method only measures acetoacetic acid and acetone 9